CD44v9 as a therapeutic target for antibody-drug conjugate in advanced breast cancer.
- DOI
- 10.1016/j.biopha.2026.119113
- Published
- 2026 Mar
- Container
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.biopha.2026.119113,
title = {CD44v9 as a therapeutic target for antibody-drug conjugate in advanced breast cancer.},
author = {Reddy DR and Flynn ME and Anami Y and Yang Z and Aleman J and Seo M and Tsuchikama K and Maynard JA and Ueno NT and Lee J},
year = {2026},
journal = {Biomedicine \& pharmacotherapy = Biomedecine \& pharmacotherapie},
doi = {10.1016/j.biopha.2026.119113},
url = {https://doi.org/10.1016/j.biopha.2026.119113}
}RIS
TY - JOUR TI - CD44v9 as a therapeutic target for antibody-drug conjugate in advanced breast cancer. AU - Reddy DR AU - Flynn ME AU - Anami Y AU - Yang Z AU - Aleman J AU - Seo M AU - Tsuchikama K AU - Maynard JA AU - Ueno NT AU - Lee J PY - 2026 JO - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie DO - 10.1016/j.biopha.2026.119113 UR - https://doi.org/10.1016/j.biopha.2026.119113 ER -
APA
DR, R., ME, F., Y, A., Z, Y., J, A., M, S., K, T., JA, M., NT, U., & J, L. (2026). CD44v9 as a therapeutic target for antibody-drug conjugate in advanced breast cancer.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. https://doi.org/10.1016/j.biopha.2026.119113
Source records
- pubmed · retrieved 2026-09-26T03:30:42.421Z
- europe-pmc · retrieved 2026-09-26T03:30:42.450Z